Sign in
TerminatedPhase 3

A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy

Key facts

Who runs it
Jiangsu HengRui Medicine Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 3
People taking part
391 people enrolled
Started
1 Nov 2021
Ended
6 Sept 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • SHR3680
  • Placebo
Record updated
3 April 2026
Why it stopped
Due to the adjustment of the sponsor's development plan, after discussion with leading PI, sponsor has decided to terminate this study.

Who can take part

Age
18 years and older
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age of ≥ 18 years old
  • ECOG PS score of 0 or 1
  • Pathologically diagnosed as prostate adenocarcinoma
  • High-risk patients
  • No distant metastasis (clinical staging of M0) as determined by BICR of imaging examinations
  • Subjects who are candidates for and plan to undergo radical prostatectomy (removal of the entire prostate and seminal vesicle plus pelvic lymphadenectomy)

Who cannot take part

  • Subjects who received any prior treatment for prostate cancer, except medical ADT and/or first-generation androgen receptor antagonists (such as bicalutamide) for not more than 4 weeks
  • Subjects who received any other investigational products or underwent major surgery within 4 weeks prior to randomization
  • Subjects with dysphagia, chronic diarrhea, intestinal obstruction, or other factors affecting drug intake and absorption
  • Subjects with a history of epilepsy, or diseases that can induce seizures occurred within 12 months prior to randomization (including a history of transient ischemic attack, stroke, traumatic brain injury, and cognitive impairment, requiring hospitalization)
  • Subjects with active heart disease within 6 months prior to randomization, including: severe/unstable angina pectoris, myocardial infarction, symptomatic congestive heart failure, and ventricular arrhythmias requiring medical treatment
  • Subjects who are planning bilateral orchidectomy during the treatment period of the study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study is being conducted to evaluate the efficacy and safety of SHR3680 plus androgen deprivation therapy (ADT) vs. placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer using pathologic complete response (pCR) rate and metastasis-free survival (MFS).

The 2 groups in the trial

  • Treatment group:SHR3680 + ADTTreatment being tested

    Treatment: SHR3680

  • Treatment group : Placebo + ADTPlacebo, for comparison

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase III Randomized, Placebo-Controlled, Double-Blind Study of SHR3680 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Patients With High-Risk Localized or Locally Advanced Prostate Cancer Undergoing Radical Prostatectomy
Record updated
3 April 2026